Cover Image
Read Now

Clinical review report: Tapentadol hydrochloride extended-release tablet (Nucynta extended-release) (Paladin labs inc.)

The objective of this review is to perform a systematic review of the beneficial and harmful effects of tapentadol hydrochloride extended-release tablets (Nucynta Extended-Release) 100 mg to 250 mg twice a day for the management of pain severe enough to require daily, continuous, long-term opioid tr...

Full description

Bibliographic Details
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2018, October 2018
Edition:Final
Series:CADTH common drug review
Subjects:
Analgesics, Opioid / Therapeutic Use
Canada
Tapentadol
Acute Pain / Drug Therapy
Delayed-action Preparations
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:The objective of this review is to perform a systematic review of the beneficial and harmful effects of tapentadol hydrochloride extended-release tablets (Nucynta Extended-Release) 100 mg to 250 mg twice a day for the management of pain severe enough to require daily, continuous, long-term opioid treatment, and: that is opioid responsive; and for which alternative treatment options are inadequate. Nucynta Extended-Release is not indicated as an as-needed analgesic
Item Description:"Indication: Management of pain severe enough to require daily, continuous, long-term opioid treatment, and: that is opioid responsive; and for which alternative treatment options are inadequate. Tapentadol extended-release tablet is not indicated as an as-needed (prn) analgesic."
Physical Description:1 PDF file (161 pages) illustrations

Similar Items